Petra Laeis
About
Petra Laeis is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Petra Laeis has authored 45 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Cardiology and Cardiovascular Medicine, 11 papers in Internal Medicine and 10 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Petra Laeis's work include Atrial Fibrillation Management and Outcomes (22 papers), Cardiac Arrhythmias and Treatments (15 papers) and Blood Pressure and Hypertension Studies (11 papers). Petra Laeis is often cited by papers focused on Atrial Fibrillation Management and Outcomes (22 papers), Cardiac Arrhythmias and Treatments (15 papers) and Blood Pressure and Hypertension Studies (11 papers). Petra Laeis collaborates with scholars based in Germany, Italy and Spain. Petra Laeis's co-authors include Kurt Püchler, Wilhelm Kirch, Paul‐Egbert Reimitz, Wolfgang Zierhut, Lars Eckardt, Marco Valgimigli, Thorsten Lewalter, Rüdiger Smolnik, Andreas Goette and Klaus O. Stumpe and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and European Heart Journal.
In The Last Decade
Petra Laeis
44 papers receiving 1.2k citations
Hit Papers
Peers
Petra Laeis
Maximilian T. Lobmeyer United States
Carlos Escobar Spain
Jeanne Mendell United States
Yasser Khder France
James W. Hainer United States
Steen Dalby Kristensen Denmark
Simon de Denus Canada
Robert Dubiel United States
Jessie Wang United States
A.M.H.P. van den Besselaar Netherlands
Citations per year, relative to Petra Laeis Petra Laeis (= 1×)
peers
Maximilian T. Lobmeyer
Countries citing papers authored by Petra Laeis
Since
Specialization
Citations
This map shows the geographic impact of Petra Laeis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Laeis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Laeis more than expected).
Fields of papers citing papers by Petra Laeis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Petra Laeis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Laeis. The network helps show where Petra Laeis may publish in the future.
Co-authorship network of co-authors of Petra Laeis
This figure shows the co-authorship network connecting the top 25 collaborators of Petra Laeis. A scholar is included among the top collaborators of Petra Laeis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Laeis. Petra Laeis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Agnelli, Giancarlo, Ulrich Hoffmann, Pierre Hainaut, et al.. (2025). Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe. Thrombosis and Haemostasis. 125(9). 880–892.
2.
Kirchhof, Paulus, Ameet Bakhai, Carlo de Asmundis, et al.. (2024). Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study. International Journal of Cardiology. 408. 132118–132118.
3.
Guarneri, Valentina, François P. Duhoux, Daniel Egle, et al.. (2024). Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Future Oncology. 20(18). 1237–1250.
4.
Palmerini, Emanuela, John H. Healey, Nicholas M. Bernthal, et al.. (2023). Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies. The Oncologist. 28(6). e425–e435.
5.
Kirchhof, Paulus, Ameet Bakhai, Joris R. de Groot, et al.. (2023). Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year follow-up of more than 13,000 patients from the ETNA-AF-Europe study. European Heart Journal. 44(Supplement_2).
6.
Kirchhof, Paulus, Ladislav Pecen, Ameet Bakhai, et al.. (2022). Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care. European Heart Journal - Cardiovascular Pharmacotherapy. 9(1). 47–57.
7.
Bernthal, Nicholas M., John H. Healey, Emanuela Palmerini, et al.. (2021). The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet Journal of Rare Diseases. 16(1). 191–191.
8.
Agnelli, Giancarlo, Ulrich Hoffmann, Pierre Hainaut, et al.. (2020). ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thrombosis Research. 196. 297–304.
9.
Unverdorben, Martin, Christian von Heymann, Amparo Santamaría, et al.. (2020). Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. BMC Cardiovascular Disorders. 20(1). 504–504.
10.
Caterina, Raffaele De, Peter J. Kelly, Pedro Monteiro, et al.. (2019). Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovascular Disorders. 19(1). 165–165.
11.
Cohen, Alexander T., Anselm K. Gitt, Rupert Bauersachs, et al.. (2017). The management of acute venous thromboembolism in clinical practice. Thrombosis and Haemostasis. 117(7). 1326–1337.
12.
Hanon, Olivier, Jean‐Sébastien Vidal, Jean-Yves Le Heuzey, et al.. (2017). Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. International Journal of Cardiology. 232. 98–104.
13.
Volpe, Massimo, Alejandro de la Sierra, Bettina Ammentorp, & Petra Laeis. (2014). Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension. Advances in Therapy. 31(5). 561–574.
14.
Volpe, Massimo, Lars Christian Rump, Bettina Ammentorp, & Petra Laeis. (2012). Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination. Clinical Drug Investigation. 32(10). 649–664.
15.
Sellin, Lorenz, Johannes Stegbauer, Petra Laeis, & Lars Christian Rump. (2005). Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. Journal of Hypertension. 23(11). 2083–2092.
16.
Brunner, Hans R. & Petra Laeis. (2003). Clinical efficacy of olmesartan medoxomil. Journal of Hypertension. 21(2). S43–S46.
17.
Bergmann, Klaus von, et al.. (2001). Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. Journal of Hypertension. 19(1). S33–S33.
18.
Laeis, Petra, Kurt Püchler, & Wilhelm Kirch. (2001). The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. Journal of Hypertension. 19(1). S21–S32.
19.
Vega, Gloria Lena, Klaus von Bergmann, Scott M. Grundy, et al.. (1999). Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol. Journal of Internal Medicine. 246(1). 1–9.
20.
Stumpe, Klaus O., Enrico Agabiti‐Rosei, Jürgen Scholze, et al.. (1970). Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maximilian T. Lobmeyer Breakdown of academic impact, for papers by Carlos Escobar Breakdown of academic impact, for papers by Jeanne Mendell Breakdown of academic impact, for papers by Yasser Khder Breakdown of academic impact, for papers by James W. Hainer Breakdown of academic impact, for papers by Steen Dalby Kristensen Breakdown of academic impact, for papers by Simon de Denus Breakdown of academic impact, for papers by Robert Dubiel Breakdown of academic impact, for papers by Jessie Wang Breakdown of academic impact, for papers by A.M.H.P. van den Besselaar